Chongqing Xiwei Medical Technology Co., Ltd.

To investigate the pharmacokinetic characteristics of a single oral administration of isavuconazole sulfate capsules [test preparation T, specification: 100 mg (calculated as C22H17F2N5OS)] provided by Chongqing Xiwei Pharmaceutical Technology Co., Ltd. to healthy subjects under fasting and postprandial conditions and a single oral administration of isavuconazole sulfate capsules [reference preparation R, trade name: Kangxinbo®/CRESEMBA®, specification: 100 mg (calculated as C22H17F2N5OS)] certified by Basilea Pharmaceutica Deutschland GmbH under the same conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.

Main research purpose: According to the relevant provisions of bioequivalence test, Merck Sharp & Dohme B.V. was selected as the reference preparation, and the test preparation Letermovir Tablets (Specification: 240mg) produced by Chongqing Boteng Pharmaceutical Co., Ltd. and provided by Chongqing Xiwei Pharmaceutical Technology Co., Ltd. were used for fasting and postprandial human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation Letermovir Tablets (Specification: 240mg) and the reference preparation Letermovir Tablets (Trade Name: Prevymis (Pureming), Specification: 240mg) in healthy subjects.

Primary objective: To evaluate the bioequivalence of the test formulation (Metformin Empagliflozin Tablets produced by Chongqing Huasen Pharmaceutical Co., Ltd., specifications: each tablet contains 1000 mg of metformin hydrochloride and 12.5 mg of empagliflozin) and the reference formulation (Metformin Empagliflozin Tablets produced by Boehringer Ingelheim Promeco S.A. de C.V., specifications: each tablet contains 1000 mg of metformin hydrochloride and 12.5 mg of empagliflozin, trade name: Synjardy ®) in Chinese healthy subjects under fasting and fed conditions, using the main pharmacokinetic parameters (AUC and Cmax) of metformin Empagliflozin as bioequivalence evaluation indicators. Secondary objective: To observe the safety of oral administration of the test formulation and the reference formulation under fasting and fed conditions.